Growth Equity Opportunities 18 VGE LLC 13D and 13G filings for X4 Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-05-26 3:03 pm Purchase |
2023-05-18 | 13D | X4 Pharmaceuticals, Inc. XFOR |
Growth Equity Opportunities 18 VGE LLC | 15,742,792 9.990% |
3,605,999 (+29.71%) |
Filing |
| 2022-12-19 5:31 pm Purchase |
2022-12-09 | 13D | X4 Pharmaceuticals, Inc. XFOR |
Growth Equity Opportunities 18 VGE LLC | 12,136,793 9.990% |
5,258,636 (+76.45%) |
Filing |
| 2022-07-19 5:28 pm Purchase |
2022-07-06 | 13D | X4 Pharmaceuticals, Inc. XFOR |
Growth Equity Opportunities 18 VGE LLC | 6,878,157 9.900% |
6,878,157 (New Position) |
Filing |